ABSTRACT The nonimmunogenic thymic leukemia TH, obtained in mouse strain CBA/Ht, was adapted to culture. By in vitro treatment ofa clonal TH cell line with the mutagen N-methyl-N'-nitro-N-nitrosoguanidine, stable variant cell clones (tumi) were obtained that elicited a rejection response in syngeneic mice. Mice that had rejected a tum-variant were partially protected against a challenge with the original tumor. When spleen cells of these animals were restimulated in vitro, cytolytic T cells were obtained that were directed against an antigen present on the original tumor. The existence of these cytolytic effectors was confirmed by clonal analysis of the cytolytic response. No immune protection against TH was observed in mice that had been immunized with irradiated cells of the original TH tumor. These results confirm that tum-variants can elicit a syngeneic rejection response against tumors that are apparently devoid of transplantation immunogenicity. The experimental conditions and the results make it likely but not certain that the tumor-associated antigen detected on leukemia TH was present on the primary tumor.
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Little evidence is available to support the view that human tumors carry antigens constituting potential targets for a rejection response ofthe patient (1) . In the mouse, the existence oftumorassociated transplantation antigens has been firmly established for most virus-or carcinogen-induced tumors by protection experiments involving immunization with irradiated tumor cells (2) (3) (4) . However, for the majority of spontaneous and radiationinduced tumors, no evidence for antigenicity was obtained by this method (5, 6) .
We reported previously that, by mutagen treatment of cell lines ofthree mouse tumors-namely, teratocarcinomaOTT650, Lewis lung carcinoma, and mastocytoma P815-X2-we have obtained at high frequency stable tumor cell variants (tum-) that fail to form tumors in syngeneic mice (7) (8) (9) . These tum-variants undergo a process of immune rejection in the syngeneic host. Most tum-variants carry new singular transplantation antigens that can be demonstrated in vivo by cross-protection experiments (8) (9) (10) (11) . With the variants obtained from P815-X2 and Lewis lung carcinoma, these new antigens elicit the production of specific cytolytic T cells (10, 12) .
In rejecting tum-variants, syngeneic mice often acquire a resistance against challenge with the original tumor cell line (tum'). This is observed with tum-variants derived from two weakly immunogenic tumors, Lewis lung carcinoma and mastocytoma P815-X2 (8, 9) . More surprisingly, protection is also observed with teratocarcinoma tum-variants, even though the tum' cell line appears completely devoid oftransplantation immunogenicity (11, 13) . This protection extends to the original transplantable teratocarcinoma OTT6050, indicating the presence on this tumor ofan otherwise undetected tumor-associated transplantation antigen (14) . Unfortunately, we have been unable to elicit a cytolytic T-cell response with teratocarcinoma tum-variants, so that this conclusion could not be strengthened by demonstration of specific effector cells directed against this tumor-associated antigen.
In view of the-admittedly remote-possibility of applying to human tumors the protection conferred by tum-variants, it was considered worthwhile to see whether our observations could be extended to other weakly or nonimmunogenic mouse tumors in conditions approaching those applying to primary tumors. This implied avoiding as far as possible artefactual antigenicity that can result from genetic differences between the primary tumor bearer and the experimental mice or from antigenic evolution of the tumor cells either in vivo or in vitro. For this purpose, we chose CBA thymic leukemia TH that had not been adapted to culture and had always been transplanted in a carefully maintained inbred colony (CBA/Ht). Leukemia TH was isolated by Hewitt from a female CBA/Ht mouse that had been repeatedly exposed to yirradiation 6-3 months earlier so as to receive a cumulative dose of 1,800 rads (1 rad = 0.01 gray; ref. 5 (Table 1 ). This protection was particularly significant in mice that had been injected with variant THi18. This tum-variant also conferred protection against the transplanted tumor THt, indicating that the relevant tumor-associated transplantation antigen is not an artefact induced by adaptation to culture. CTL Activity. To find out whether the antigen detected in vivo on tumor TH could also be found in vitro, we examined the CTL response of spleen cells obtained from THi18 or TH45 regressor mice. As shown in Table 2 , when such spleen cells were stimulated in vitro with the immunizing tum-variant in classical MLTC conditions, they showed a high cytolytic activity. This activity was preferentially directed against the immunizing variant, thereby indicating the presence of new individual antigens on variants TH18 and TH45. Moreover, an important cross-reactive activity was observed against all TH cells, demonstrating the presence of a common antigen. That this activity was specifically directed against a transplantation antigen of leukemia TH was suggested by the low level of lytic activity against spontaneous CBA/Ht leukemia LEB, which showed the same sensitivity as TH to anti-H-2k CTL ( (19, 20) and using them to study tum-variants (16) has been demonstrated. Using limiting-dilution microcultures (17, 18) , we estimated that, in spleen cell populations of TH18 regressor mice, the frequency of CTL precursors directed against a common TH antigen was =2 x 10-' whereas that of CTL precursors directed specifically against TH18 was 1 x 10-4. A number of CTL clones showing anti-TH18 or anti-TH activity were expanded and maintained in vitro for =20 days. The activity of two TH18-specific clones and two TH-specific clones is shown in Table 3 Spleen cells from TH18 regressor mice were stimulated in vitro as described in Table 2 with either TH18 or TH1 cells. The MLTC cells were restimulated under limiting-dilution conditions. CTL clones TH18: 1 THt, it is a weak tum-variant since only -20% of the tumors regress. We examined whether mutagen treatment of TH18 would produce secondary variants that would have a stronger tum-character and still induce protection against tum' cells.
A TH18 cell population was treated with MNNG (3 ,ug/ml for 15 min). The surviving population, amounting to 0.5% ofthe initial cells, was cloned. Of 17 clones tested, 11 Three clones isolated from the population that had been treated with mutagen twice and four clones isolated from the population that had been treated with mutagen three times (21) , has also been achieved by viral infection (21) (22) (23) , by chemical modification of the cell surface (24) , and by in vivo treatment with an antineoplastic drug (25, 26) . However, to the best ofour knowledge, none of these other procedures has been reported to result in protection against tumors that did not already have some immunogenicity of their own.
The degree of protection conferred by TH tum-variants differed from one variant to another, that obtained with TH18 being clearly superior to that obtained with TH45. Similar observations have been made with tum-variants isolated from mastocytoma P815 (9) . It is perhaps not a coincidence that, for both P815 and TH, the tum-variants that elicit the best protection are those variants that have the weakest individual "tum" antigen as judged from the response obtained either in vivo or in vitro.
Mutagen treatment of variant TH18 produced a high yield of secondary tum-variants whose tumorigenicity was found to be further reduced. A new specific antigenic determinant not present on TH18 was detected on the secondary variant TH18.21 by T-cell cytolysis. Thus, it is possible that, by repeated mutagen treatment of tumor cells, populations will be obtained in which the majority of the cells are tum-variants and most of these variants carry multiple new antigens.
Is it probable that the antigen recognized on TH was present on the primary tumor? This antigen certainly does not represent a tissue culture artefact since both the in vivo and in vitro responses are effective against tumor cells that had always been transplanted in vivo. It is more difficult to exclude the possibility that, after isolation of the tumor, there might have been some genetic change in the CBA/Ht line resulting, for instance, in the loss of a minor histocompatibility antigen that the mice would now recognize on the tumor. However, this is unlikely Immunology: Van Pel and-Boon 4722 Immunology: Van Pel and Boon because of the existence ofa CTL activity directed specifically against leukemia TH and not against leukemia LEB, which was obtained by Hewitt in his CBA/Ht mouse colony before tumor *TH. If the response was due to genetic evolution of the mice after the isolation ofleukemia TH, it should affect both tumors. Finally, there is the possibility of antigenic evolution of the tumor during its passages in vivo. This type of artefactual antigenicity is practically impossible to rule out in experiments with transplantable tumors. It has often been noticed that tumors acquire murine leukemia virus antigens in the course of their passages in vivo. However, this does not appear to apply to leukemia TH since this tumor was negative for Rauscher murine leukemia virus antigens gp70 and p30. In conclusion, we consider that it is likely but not certain that the tumor-associated antigen recognized on TH was present on the primary tumor as a potential target for a response of the primary host.
Taken together with our previous observations on a mouse teratocarcinoma (11), the results, obtained with leukemia TH suggest that there may be many tumors for which antigenicity that is not detectable by conventional immunization could become apparent in animals that have rejected tum-variants. If it is found that tum-variants elicit a significant response against other nonimmunogenic tumors under conditions that maximize the likelihood that the relevant antigen was present-on the primary tumor, the prospect ofapplying to human tumors the pro-.tection conferred by tum-variants will appear less remote.
